Showing 1196 results
- Media Release /Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an…
- Media Release /Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus…
- Media Release /New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2]…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…
- Key Release /Annonce événementielle au sens de l’art. 53 RCExercice entier Chiffre d’affaires net en hausse de +4% (tcc1, -2% USD) et résultat opérationnel core croissant de +8% (tcc, 0% USD) Innovative…
- Key Release /Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative…
- Key Release /Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T2 en hausse de +5% tcc1 (-1% USD) Innovative Medicines (IM): hausse du chiffre d’affaires de +5% (tcc, -1% USD), avec…
- Media Release /Gilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the future Sandoz BoardMr Ghostine to begin role as Sandoz Chairman following the spin-…
- Media Release /Submission supported by comprehensive analytical and clinical data package Denosumab indicated for treating variety of conditions including osteoporosis in postmenopausal women1,2 Sandoz…
- Media Release /In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week…
Pagination
- ‹ Previous page
- 1
- …
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- …
- 120
- › Next page